Drugs / Seasonal Influenza DNA vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01676402 | Aug 2012 → Apr 2014 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01609998 | Jun 2012 → Jul 2013 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Seasonal Influenza DNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01609998 ↗ |
| Modality | Vaccine | “This is a Phase I, dose escalation study in healthy adolescents and children (6-17 years) to evaluate the safety, tolerability, and immunogenicity of a prime-boost regimen of...” NCT01609998 ↗ |
| Route | Intramuscular | “Sites enrolled adolescents, followed by younger children, to receive DNA prime (1 mg or 4 mg) intramuscularly by needle-free jet injector (Biojector)” PMID 30388160 ↗ Nov 2018 |